Highlights

Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
0.0%
Return On Equity TTM
0.0%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
0.0
EPS Estimate Next Year
0.0
EPS Estimate Current Quarter
0.0

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Moderna, Inc.
Moderna, Inc.
-6.91%
25.22%
1.18%
-60.44%
769.95%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
4.48%
16.73%
49.42%
85.5%
258.18%
Novo Nordisk A/s
Novo Nordisk A/s
-3.82%
25.91%
69.01%
206.62%
460.98%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
4.51%
12.79%
36.04%
145.12%
174.23%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.18
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
32.36
32.36
1.46
44.28
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
48.58
48.58
2.36
3.45
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.75
31.75
0.53
17.06
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Moderna, Inc.
Moderna, Inc.
Buy
$48.0B
769.95%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$120.7B
258.18%
32.36
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$631.0B
460.98%
48.58
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.2B
174.23%
31.75
39.46%

Insights on NHWK

  • Increasing Revenue

    Revenue is up for the last 2 quarters, 657.77K → 723.12K (in $), with an average increase of 9.0% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, -13.89M → -13.13M (in $), with an average increase of 5.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 69.0% return, outperforming this stock by 166.0%

FAQs